Unlocking Broad COPD Control with Inhaled JAK Inhibition, Utilizing Targeted Delivery for Safer, More Effective Treatment
- Discover how inhaled pan-JAK inhibition could enable treatment across both eosinophilic and non-eosinophilic COPD phenotypes, expanding reach beyond current biologic limitations
- Explore the benefits of dry powder inhalation delivering therapy to the lungs, enhancing local efficacy while minimizing systemic exposure and improving safety profiles
- Understand how targeted pulmonary delivery of small molecules could provide a convenient, scalable alternative to biologics, supporting better patient adherence and clinical outcomes